1.During the quarter under rewiew, the Incomeof the company has grown by 15.12% and Net Profit has shown an increse of 38.07% as compared to the same period in the previous year.
2.The Company is exclusive in the pharmaceutical business segment only.
3.Information on Investor's Complaints for the quarter: Opening: nil, Received: 6,Resolved: 6, Pending: Nil
4.Previous period figures have been re-grouped/ or rearranged whenever necessary.
5.The above results were taken on record by the Audit Committee and Board of Directors at their respective meetings held on 29th January,2009.
|